These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
100 related articles for article (PubMed ID: 2042796)
1. Regional intravenous ketanserin and guanethidine therapy in Raynaud's phenomenon. Caputi CA; De Carolis G; Tomasetti C Angiology; 1991 Jun; 42(6):473-80. PubMed ID: 2042796 [TBL] [Abstract][Full Text] [Related]
2. Comparative efficacy of ketanserin and pentoxiphylline in treatment of Raynaud's phenomenon. Arosio E; Montesi G; Zannoni M; Paluani F; Lechi A Angiology; 1989 Jul; 40(7):633-8. PubMed ID: 2662829 [TBL] [Abstract][Full Text] [Related]
3. Effect of ketanserin on Raynaud's phenomenon in progressive systemic sclerosis: a double-blind trial. Lukác J; Rovenský J; Tauchmannová H; Zitnan D Drugs Exp Clin Res; 1985; 11(9):659-63. PubMed ID: 3916837 [TBL] [Abstract][Full Text] [Related]
4. Controlled comparison of ketanserin and nifedipine in Raynaud's phenomenon. Codella O; Caramaschi P; Olivieri O; Perbellini L; Perbellini A; Bambara LM; Corrocher R; De Sandre G Angiology; 1989 Feb; 40(2):114-21. PubMed ID: 2644876 [TBL] [Abstract][Full Text] [Related]
5. The use of the selective serotonin S2 receptor antagonist Ketanserin in the treatment of Raynaud's phenomenon. Dormandy JA; Berent A; Downes SJ Eur J Vasc Surg; 1988 Dec; 2(6):371-5. PubMed ID: 3075559 [TBL] [Abstract][Full Text] [Related]
6. International study of ketanserin in Raynaud's phenomenon. Coffman JD; Clement DL; Creager MA; Dormandy JA; Janssens MM; McKendry RJ; Murray GD; Nielsen SL Am J Med; 1989 Sep; 87(3):264-8. PubMed ID: 2672807 [TBL] [Abstract][Full Text] [Related]
7. New prospects for the treatment of Raynaud's phenomenon using a serotoninergic S2 receptor antagonist (ketanserin) and stable derivatives of prostacyclin. Pola P; Tondi P; Serricchio M; Favuzzi A; Gerardino L Angiology; 1993 Feb; 44(2):123-8. PubMed ID: 8434805 [TBL] [Abstract][Full Text] [Related]
8. Does serotonin receptor blockade have a therapeutic effect in Raynaud's phenomenon? Brouwer RM; Wenting GJ; Visser W; Schalekamp MA Vasa Suppl; 1987; 18():64-7. PubMed ID: 3299817 [No Abstract] [Full Text] [Related]
9. Effects of intra-arterial ketanserin in Raynaud's phenomenon assessed by 99MTc-pertechnetate scintigraphy. Kunnen JJ; Dahler HP; Doorenspleet JG; van Oene JC Eur J Clin Pharmacol; 1988; 34(3):267-71. PubMed ID: 2840293 [TBL] [Abstract][Full Text] [Related]
10. Effect of long-term ketanserin treatment on 5-HT levels, platelet aggregation and peripheral circulation in patients with Raynaud's phenomenon. A double-blind, placebo-controlled cross-over study. Arneklo-Nobin B; Elmér O; Akesson A Int Angiol; 1988; 7(1):19-25. PubMed ID: 3290356 [TBL] [Abstract][Full Text] [Related]
11. Ketanserin in the treatment of Raynaud's phenomenon associated with generalized scleroderma. Engelhart M Br J Dermatol; 1988 Dec; 119(6):751-4. PubMed ID: 3060193 [TBL] [Abstract][Full Text] [Related]
12. The diagnosis and treatment of Raynaud's phenomenon. Porter JM; Snider RL; Bardana EJ; Rösch J; Eidemiller LR Surgery; 1975 Jan; 77(1):11-23. PubMed ID: 1078555 [TBL] [Abstract][Full Text] [Related]
13. Therapeutic efficacy of ketanserin, a selective antagonist of the serotonin (5-HT2) receptors, in primary and secondary Raynaud's phenomenon. Meloni F; Transi MG; Sciacca V; De Felice C; Bagarone A; Sciacca A Angiology; 1987 Jul; 38(7):530-6. PubMed ID: 3619126 [TBL] [Abstract][Full Text] [Related]
14. Acute effects and mechanism of action of ketanserin in patients with primary Raynaud's phenomenon. Brouwer RM; Wenting GJ; Schalekamp MA J Cardiovasc Pharmacol; 1990 Jun; 15(6):868-76. PubMed ID: 1694908 [TBL] [Abstract][Full Text] [Related]
16. Ketanserin and capillary flow in Raynaud's phenomenon. Tooke JE; Williams SA; Rawlinson DW; Black C Int J Microcirc Clin Exp; 1990 Aug; 9(3):249-55. PubMed ID: 2394546 [TBL] [Abstract][Full Text] [Related]
17. Ketanserin versus nifedipine in secondary Raynaud's phenomenon. Kirch W; Linder HR; Hutt HJ; Ohnhaus EE; Mahler F Vasa; 1987; 16(1):77-80. PubMed ID: 3554811 [No Abstract] [Full Text] [Related]
18. Treatment of Raynaud's phenomenon with ketanserin in patients with connective tissue disorders. Roald OK; Seem E Br Med J (Clin Res Ed); 1984 Sep; 289(6445):577-9. PubMed ID: 6432198 [TBL] [Abstract][Full Text] [Related]
19. Treatment of the Raynaud's phenomenon with piracetam. Moriau M; Lavenne-Pardonge E; Crasborn L; von Frenckell R; Col-Debeys C Arzneimittelforschung; 1993 May; 43(5):526-35. PubMed ID: 8328997 [TBL] [Abstract][Full Text] [Related]
20. Ketanserin treatment and serotonin in patients with primary and secondary Raynaud's phenomenon. Marasini B; Biondi ML; Bianchi E; Dell'Orto P; Agostoni A Eur J Clin Pharmacol; 1988; 35(4):419-21. PubMed ID: 3197751 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]